|
|
Article: Phase III Trial With Avastin in Relapsed Metastatic Breast Cancer Does Not Meet Primary Endpoint; Results from Lead Phase III Study in Colorectal Cancer Due in Mid-2003.
- Article from:
- Business Wire
- Article date:
- September 9, 2002
CopyrightCOPYRIGHT 2002 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Medical Writers
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sept. 9, 2002
Genentech, Inc. (NYSE:DNA) today announced that a Phase III study of Avastin(TM) (bevacizumab, rhuMAb-VEGF) in relapsed metastatic breast cancer patients did not meet its primary efficacy endpoint of progression-free survival. Avastin is an investigational therapeutic antibody directed at vascular endothelial growth factor (VEGF). This study randomized 462 women with metastatic breast cancer who had previously received treatment with both anthracycline and taxane-based chemotherapy regimens to receive Avastin with Xeloda(R) (capecitabine) or Xeloda ...